<DOC>
	<DOCNO>NCT00051779</DOCNO>
	<brief_summary>This study intend evaluate safety , tolerability , possible effectiveness investigational humanize monoclonal antibody ( CAL ) parathyroid hormone-related protein ( PTHrP ) compare zoledronic acid patient breast cancer metastatic bone . The study also evaluate possible effect study drug performance status , marker bone metabolism , skeletal event related bone metastasis include elevate blood calcium level , bone pain , metastatic lesion , complication intervention . The level CAL blood also evaluate .</brief_summary>
	<brief_title>An Investigational Drug ( CAL ) Versus Zoledronic Acid ( Zometa® ) Patients With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<criteria>Major Inclusion Criteria – Others Stipulated within Protocol The study physician must assure have/are : Must female least 18 year age use effective form birth control . A documented history breast cancer least one bone metastasis previously treat radiation surgery , anticipate treat within next 24 week . A total body bone scan radiographic scan ( ) perform within 4 week prior screen period sufficient image sit bone metastasis . You must willing perform daily telephone diary willing keep paper diary provide voluntary consent participate study . Major Exclusion Criteria – Others Stipulated within Protocol The study physician must assure have/are : A change analgesic ( pain relief ) type medication screen period ( example , nonnarcotic narcotic ) . Received radiation therapy bone metastasis start new course chemotherapy within 3 week prior screen visit screen period . Used bisphosphonate type drug 30 day prior anticipate first dose study drug Vertebral spine weightbearing bone metastasis would place imminent risk fracture surgical intervention . Evidence active infection immune deficiency , renal failure , abnormal liver function , serum calcium level &gt; 10.1 mg/dL . Use investigational drug within 30 day prior screen .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2004</verification_date>
	<keyword>CAL</keyword>
	<keyword>Parathyroid hormone-related protein ( PTHrP )</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Bone Metastasis</keyword>
	<keyword>Hypercalcemia</keyword>
</DOC>